For most of the last decade, ophthalmology practice acquisitions happened quietly. A PE platform would acquire a mid-size group, a hospital system would absorb a retiring surgeon's panel, and the broader capital markets paid almost no attention because the deal sizes were too small and the specialty was too niche to register on anyone's radar.

That changed in the 2nd half of 2025, and the shift is visible in the federal filings.

What the SEC Data Shows

Every private capital raise in the United States above a certain threshold is required to file a Form D with the Securities and Exchange Commission. These filings are public, searchable, and updated quarterly. They don't tell you everything about a deal, but they tell you that capital was raised, how much, and by whom.

In Q3 2025, there were 500 healthcare-related Form D filings nationally, representing $8.3B in capital being raised across the sector. By Q4, that number had jumped to 674 filings and $13.7B in capital, a 35% increase in filings and a 65% increase in capital quarter over quarter.

The vision and ophthalmology subset moved even faster. Q3 had 16 filings with a combined raise target of $70M. Q4 had 41 filings with a combined target of $460M. That's a 156% increase in filings and a 557% increase in capital raising in a single quarter.

Most of those 41 filings are pharmaceutical companies, device manufacturers, and biotech firms developing treatments for conditions like dry eye, glaucoma, and retinal degeneration. They aren't practice acquirers. But the capital acceleration tells a broader story: ophthalmology as a sector is attracting attention from investors who weren't looking at it 12 months ago, and that attention eventually flows downstream into practice-level transactions.

The Platforms Already in the Market

The established PE platforms in ophthalmology have been operating for years and their footprints are well known within the industry.

The largest platforms operate across 10 to 15 states with 100s of locations, backed by institutional PE sponsors managing funds in the $100Ms to $500Ms. They acquire multi-provider groups and mid-size practices, typically targeting $5M or more in EBITDA per transaction. Their deal flow comes through brokers and institutional channels, and the physicians who sell to them generally become employees of the platform post-close with optional equity rollover.

These platforms built the playbook for ophthalmology consolidation, and they've done it effectively at their scale. But their scale is exactly what creates the gap.

The Gap Nobody Is Filling

A solo ophthalmology practice generating $1M to $3M in annual revenue sits below the floor of every major PE platform operating in the space. The economics of the practice are sound, but the economics of deploying a $200M or $500M fund into $1.5M deals don't work. The overhead of sourcing, diligencing, and closing a $1.5M acquisition is roughly the same as closing a $15M acquisition, which means the fund's operational cost per dollar deployed is 10x higher at the smaller deal size. So they skip it.

On the other side, individual physicians who might want to acquire a colleague's practice face their own barriers. Student debt, limited access to financing, no operational infrastructure, and no experience running an acquisition process that involves legal structuring, payer contract assignment, credentialing transitions, and staff retention planning. The traditional buyer, the younger surgeon who would have bought the practice 20 years ago, barely exists anymore.

The result is a market where thousands of solo practices are approaching transition age with strong revenue, established patient panels, and trained staff, and the buyer pool for those practices is almost empty. The practices are too small for PE and too complex for individual buyers, and the capital that could fill the gap hasn't organized around it yet.

164.9 Million Americans in Critical Gaps

The supply problem isn't just about retiring physicians. It's about where those physicians practice relative to the populations that need them.

Cross-referencing the federal provider registry against Census population data at the ZIP code level reveals that 164.9M Americans live in areas classified as critical ophthalmology gaps, meaning 5 or fewer ophthalmologists per 100,000 residents. Another 54.9M live in underserved areas with 5 to 15 providers per 100,000. Combined, that's nearly 220M people in communities where access to ophthalmology care is already strained before a single physician retires.

The states with the lowest provider density nationally include Wyoming, Idaho, Nevada, Utah, Indiana, Arizona, and Texas, all below 8 ophthalmologists per 100,000 residents. But the gap isn't limited to rural areas. Major suburban ZIP codes in New Jersey, Texas, New York, and California with populations over 100,000 have fewer than 5 ophthalmologists serving the entire community.

When a solo practitioner in one of those ZIP codes retires without a succession plan, the patients don't just lose their doctor. They lose access to ophthalmology care entirely, because there's nobody else in the area to absorb that panel. The practice closes, the patients scatter, and the gap that was already critical gets worse.

What the New Capital Signals Mean

The Q4 2025 Form D data shows that new entrants are beginning to appear in the ophthalmology practice acquisition space. Some are physician-led, raising single-digit millions and deploying quickly into specific geographies. Others are traditional PE vehicles with larger targets and longer deployment timelines. A few have already closed their raises and appear to be acquiring quietly without public announcements.

What's notable isn't any individual filing. It's the pattern. 12 months ago, the ophthalmology practice acquisition market had effectively 2 types of participants: large established platforms operating at $5M+ EBITDA and individual physicians trying to buy a colleague's practice on their own. The space between those 2 was empty.

That space is starting to fill, and the new entrants are arriving with capital, deal structures, and in some cases physician networks that didn't exist in this segment a year ago. The early window that allowed an operator to build relationships and acquire practices without competition is still open, but the Q4 data is the 1st concrete signal that the window has a timeline.

Why Structure Matters More Than Speed

The instinct when you see capital accelerating into a market is to move fast. In ophthalmology practice acquisitions, speed without the right structure is worse than waiting.

A 68-year-old ophthalmologist who built a practice over 30 years isn't going to sell to the 1st person who shows up with a checkbook. These transitions depend on trust, clinical credibility, and a demonstrated commitment to the physician's legacy and patient base. The acquirer who builds those relationships over months and closes a deal where the physician feels respected and the staff keeps their jobs will acquire the best practices at fair terms. The acquirer who rushes in with capital and no clinical credibility will either overpay for the practices nobody else wanted or get turned away by the physicians who have better options.

The capital acceleration visible in the Q4 data validates the thesis. It also clarifies the timeline. The practices that change hands in the next 2 to 3 years will do so at multiples that reflect a thin buyer market. The practices that come to market in 2029, after the opportunity has been written about in trade publications and presented at conferences, will trade in a market with real competition and higher pricing.

For physicians approaching transition, the signal is that the market they've been waiting for someone to organize around them is starting to take shape. The time to begin the conversation about what a structured transition looks like is before the new entrants start calling.

For capital allocators evaluating this space, the signal is that the demographic thesis is now attracting attention beyond the established platforms. The advantage of entering during the relationship phase rather than the competitive phase is measurable, and the Q4 data suggests the transition between those 2 phases has begun.

This content is educational and reflects publicly available data from SEC EDGAR Form D filings (Q3+Q4 2025), the CMS National Provider Registry (NPPES June 2025), and the U.S. Census Bureau American Community Survey (2022). It does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any investment decisions should be based on a complete review of offering documents and consultation with qualified legal and financial advisors.

Verdira is a healthcare acquisition platform focused on ophthalmology practices, built around physician ownership, transparent structure, and no volume quotas. If you're exploring a different model, contact us today.

Contact info@verdira.com | 307-381-3734 | verdira.com